Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation


H2020 grant awarded to international consortium (REGAIN) to develop a drug to treat hearing loss

September 07 2015

Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. 

Hearing loss in children and youngsters hinders language learning and cognitive development. Acquired hearing loss in adults impairs social integration and participation, and accelerates the progression of cognitive impairment. The treatment of hearing loss is currently limited to the use of hearing aids or cochlear implants. These devices often perform poorly in noisy environments and can be very costly. 

The international REGAIN (REgeneration of inner ear hair cells with GAmma-secretase INhibitors) consortium is a collaboration between 7 highly dedicated partners, coordinated by the Dutch company Audion Therapeutics BV and the UCL Ear Institute, University of Tübingen, The National and Kapodistrian University of Athens, Eli Lilly, Clinquest Services and ttopstart BV (project management). The REGAIN consortium aims to develop a locally delivered small-molecule drug to treat hearing loss caused by the loss of sensory hair cells in the inner ear. It is REGAINs ambition to perform a proof of concept clinical study utilizing this approach. This project has been awarded a 5,8 million Euro Horizon 2020 grant to develop a drug to treat hearing loss.

This research is funded by the European Commission in the Horizon 2020 - research and innovation framework programme.


(an extended version of this news message is available as a press release)

Share this